Department of Radiotherapy and Radiation Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, 221005, India.
Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
J Cancer Res Clin Oncol. 2023 Dec;149(19):16983-16992. doi: 10.1007/s00432-023-05397-4. Epub 2023 Sep 23.
This study aimed to evaluate the survival outcomes and identify prognostic factors for patients with oral cavity cancer (OCC) who underwent adjuvant treatment with volumetric arc therapy (VMAT) using simultaneous integrated boost (SIB).
Data was collected for post-operated patients of carcinoma of oral cavity who received adjuvant VMAT with SIB between June 2018 and December 2022. The data was entered and analyzed using SPSS software version 20.0. Survival rates were estimated using Kaplan Meier method. To determine survival difference between the groups, log rank test was used. Multivariate analyses were performed with Cox proportional hazard model and p value < 0.05 was considered as significant.
A total of 178 patients were included in the study. The median follow-up period was 26 months (range 3-56 months). The 3-year OS, DFS, and LRC rates were 78% (95% CI 77-79%), 76% (95% CI 74-77%), and 81% (95% CI 80-82%), respectively. Univariate analysis identified age ≥ 50 years, lymph node involvement, extracapsular extension (ECE), and N2-N3 disease as significant adverse prognostic factors for OS, DFS, and LRC. Multivariate analysis confirmed age ≥ 50 years and nodal involvement as independent predictors of worse OS, DFS, and LRC. Additionally, ECE independently affected OS and DFS.
Adjuvant treatment with VMAT using SIBin patients with OCC is effective. Age and nodal involvement had significant impact on LRC, DFSand OS while ECE on DFSand OS.
本研究旨在评估接受容积弧形治疗（VMAT）同步整合boost（SIB）辅助治疗的口腔癌（OCC）患者的生存结果，并确定其预后因素。
收集了 2018 年 6 月至 2022 年 12 月接受术后 VMAT 同步整合 boost 辅助治疗的口腔癌患者的数据。使用 SPSS 软件版本 20.0 输入和分析数据。使用 Kaplan-Meier 方法估计生存率。使用对数秩检验确定组间生存差异。使用 Cox 比例风险模型进行多变量分析，p 值<0.05 被认为具有统计学意义。
共纳入 178 例患者。中位随访时间为 26 个月（范围 3-56 个月）。3 年 OS、DFS 和 LRC 率分别为 78%（95%CI 77-79%）、76%（95%CI 74-77%）和 81%（95%CI 80-82%）。单因素分析发现年龄≥50 岁、淋巴结受累、包膜外侵犯（ECE）和 N2-N3 疾病是 OS、DFS 和 LRC 的显著不良预后因素。多因素分析证实年龄≥50 岁和淋巴结受累是 OS、DFS 和 LRC 的独立预测因素。此外，ECE 独立影响 OS 和 DFS。
在 OCC 患者中使用 SIB 的 VMAT 辅助治疗是有效的。年龄和淋巴结受累对 LRC、DFS 和 OS 有显著影响，而 ECE 对 DFS 和 OS 有影响。
